{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:18:17Z","timestamp":1786490297940,"version":"build-2736575974"},"reference-count":15,"publisher":"Akademiai Kiado Zrt.","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p>Among their beneficial effects, non-steroidal anti-inflammatory drugs may also exert several side effects which depend on the dosage and the type of these medications. The most frequent gastrointestinal side effects usually develop shortly after the beginning of their administration, but others such as cardiovascular interactions (which are present much less frequently than gastrointestinal side effects) can also occur after the beginning of drug administration without a latency period. For a long-term treatment, non-steroidal anti-inflammatory drugs are most frequently used in the elderly population where patients typically have high cardiovascular risk and take other medicines, e.g. low dose acetylsalicylic acid that can interact with non-steroidal anti-inflammatory drugs; in this aspect diclofenac may cause less side effects. In this review, the authors briefly review cardiovascular side effects of non-steroidal anti-inflammatory drugs, the processes which potentially influence them, therapeutic consequences and their interaction with acetylsalicylic acid. Orv. Hetil., 2015, 156(13), 516\u2013520.<\/jats:p>","DOI":"10.1556\/oh.2015.30120","type":"journal-article","created":{"date-parts":[[2015,3,22]],"date-time":"2015-03-22T01:02:33Z","timestamp":1426986153000},"page":"516-520","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations.<i>Diclofenac is not more dangerous<\/i>"],"prefix":"10.1556","volume":"156","author":[{"given":"Viktor J\u00f3zsef","family":"Horv\u00e1th","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika Budapest Kor\u00e1nyi S. u. 2\/A 1083"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy. \u00c1d\u00e1m","family":"Tab\u00e1k","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika Budapest Kor\u00e1nyi S. u. 2\/A 1083"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika Budapest Kor\u00e1nyi S. u. 2\/A 1083"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Putz","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika Budapest Kor\u00e1nyi S. u. 2\/A 1083"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba G\u00e9za","family":"Ko\u00f3s","sequence":"additional","affiliation":[{"name":"Europ-Med Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont Buda\u00f6rs"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar I. Belgy\u00f3gy\u00e1szati Klinika Budapest Kor\u00e1nyi S. u. 2\/A 1083"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"<i>McGettigan, P., Henry, D.:<\/i> Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med., 2013, <i>10<\/i>(2), e1001388. doi: 10.1371\/journal.pmed.1001388.","DOI":"10.1371\/journal.pmed.1001388"},{"key":"2","doi-asserted-by":"crossref","unstructured":"<i>Bombardier, C., Laine, L., Reicin, A., et al.:<\/i> Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 2000, <i>343<\/i>(21), 1520\u20131528.","DOI":"10.1056\/NEJM200011233432103"},{"key":"3","doi-asserted-by":"crossref","unstructured":"<i>Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration, Bhala, N., Emberson, J., Mehri, A., et al.:<\/i> Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 2013, <i>382<\/i>(9894), 769\u2013779.","DOI":"10.1016\/S0140-6736(13)60900-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"<i>Conroy, R. M., Py\u00f6r\u00e4l\u00e4, K., Fitzgerald, A. P., et al.:<\/i> Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J., 2003, <i>24<\/i>(11), 987\u20131003.","DOI":"10.1016\/S0195-668X(03)00114-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"<i>Hippisley-Cox, J., Coupland, C., Robson, J., et al.:<\/i> Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ, 2010, <i>341,<\/i> cc6624.","DOI":"10.1136\/bmj.c6624"},{"key":"6","doi-asserted-by":"crossref","unstructured":"<i>Sirois, C., Couture, J., Gr\u00e9goire, J. P.:<\/i> Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks? Ther. Adv. Drug Saf., 2012, <i>3<\/i>(5), 213\u2013226.","DOI":"10.1177\/2042098612451267"},{"key":"7","unstructured":"<i>Kolber, M., Sharif, N., Marceau R., et al.:<\/i> Family practice patients\u2019 use of acetylsalicylic acid for cardiovascular disease prevention. Can. Fam. Physician, 2013, <i>59<\/i>(1), 55\u201361."},{"key":"8","doi-asserted-by":"crossref","unstructured":"<i>Anzellotti, P., Capone, M. L., Jeyam, A., et al.:<\/i> Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthtitis Rheum., 2011, <i>63<\/i>(3), 850\u2013859.","DOI":"10.1002\/art.30175"},{"key":"9","doi-asserted-by":"crossref","unstructured":"<i>Biondi-Zoccai, G. G., Lotrionte, M., Agostoni, P., et al.:<\/i> A systematic review and meta-analysis on the hazards of discontinuing or not-adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur. Heart J., 2006, <i>27<\/i>(22), 2667\u20132674.","DOI":"10.1093\/eurheartj\/ehl334"},{"key":"10","doi-asserted-by":"crossref","unstructured":"<i>Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., et al.:<\/i> Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med., 2001, <i>345<\/i>(25), 1809\u20131817.","DOI":"10.1056\/NEJMoa003199"},{"key":"11","doi-asserted-by":"crossref","unstructured":"<i>Saxena, A., Balaramnavar, V. M., Hohlfeld, T., et al.:<\/i> Drug\/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur. J. Pharmacol., 2013, <i>721<\/i>(1\u20133), 215\u2013224.","DOI":"10.1016\/j.ejphar.2013.09.032"},{"key":"12","doi-asserted-by":"crossref","unstructured":"<i>Meek, I. L., Vonkeman, H. E., Kasemier, J., et al.:<\/i> Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur. J. Clin. Pharmacol., 2013, <i>69<\/i>(3), 365\u2013371.","DOI":"10.1007\/s00228-012-1370-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"<i>Curtis, J. P., Wang, Y., Portnay, E. L., et al.:<\/i> Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ, 2003, <i>327<\/i>(7427), 1322\u20131323.","DOI":"10.1136\/bmj.327.7427.1322"},{"key":"14","doi-asserted-by":"crossref","unstructured":"<i>Patel, T. N., Goldberg, K. C.:<\/i> Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch. Intern. Med., 2004, <i>164<\/i>(8), 852\u2013856.","DOI":"10.1001\/archinte.164.8.852"},{"key":"15","doi-asserted-by":"crossref","unstructured":"<i>Bello, A. E., Holt, R. J.:<\/i> Cardiovascular risk with non-steroidal anti-inflammatory drugs: Clinical implications. Drug Saf., 2014, <i>37<\/i>(11), 897\u2013902.","DOI":"10.1007\/s40264-014-0207-2"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2015.30120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:57:10Z","timestamp":1590141430000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2015.30120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":15,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1556\/OH.2015.30120"],"URL":"https:\/\/doi.org\/10.1556\/oh.2015.30120","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}